本文選題：高血壓性腦出血 + 單側(cè)基底節(jié)區(qū)��； 參考：《山西醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:對入組的患者進(jìn)行多重分析比較,探討改善循環(huán)藥物銀杏葉提取物(EGb761)在高血壓性腦出血中的應(yīng)用時機及評估其安全性,為臨床工作中銀杏葉提取物在腦出血中的應(yīng)用時機選擇提供理論支持。方法:將2015年6月至2016年9月在山西省人民醫(yī)院神經(jīng)內(nèi)科住院的且符合本研究入組標(biāo)準(zhǔn)的90例單側(cè)基節(jié)區(qū)高血壓性腦出血患者按入院順序分為試驗1組、試驗2組和對照組各30例。在入組時完成對所有患者的一般資料記錄,包括登記年齡、收縮壓、舒張壓、體溫、入院時血糖、入院延遲時間,并同時收集發(fā)病當(dāng)天頭顱CT血腫體積、NIHSS評分等數(shù)據(jù)。3組皆參照中華醫(yī)學(xué)會于2014年頒布的《中國腦血管病防治指南》指導(dǎo)確定治療的方案。試驗1組在發(fā)病后1周加用EGb761注射液70mg靜滴1次/日,試驗2組發(fā)病2周后加用EGb761注射液70mg靜滴1次/日,治療14天,同時進(jìn)行頭顱CT血腫體積、NIHSS評分的數(shù)據(jù)收集,并分別與入院時頭顱CT血腫體積與NIHSS評分做差求得差值,記錄3組神經(jīng)功能缺失評分差值及血腫體積差值。在完成相關(guān)數(shù)據(jù)收集后,以spss17.0統(tǒng)計軟件進(jìn)行數(shù)據(jù)處理,以方差分析推測組間是否具有差異,采用SNK-q檢驗進(jìn)行各組間均數(shù)之間的兩兩全面比較,預(yù)設(shè)P0.05有統(tǒng)計學(xué)意義。結(jié)果:1.3組患者入院時的年齡、收縮壓與舒張壓、即刻血糖值、體溫、入院延遲時間經(jīng)統(tǒng)計分析檢驗后表明差異無統(tǒng)計學(xué)意義具有可比性(P0.05)。2.3組患者顱內(nèi)血腫體積的差值及NIHSS評分差值行正態(tài)性檢驗和方差齊性檢驗符合正態(tài)分布及方差齊性,經(jīng)方差分析可知3組患者的血腫體積差值及NIHSS評分差值之間有差異,并具有統(tǒng)計學(xué)意義(P0.05)。3.通過對3組患者顱內(nèi)血腫體積的差值及NIHSS評分差值的兩兩比較發(fā)現(xiàn)對照組與實驗1組、對照組與實驗2組、實驗2組與實驗1組患者頭顱血腫體積差值及NIHSS評分差值有差別,實驗2組患者頭顱血腫體積差值及NIHSS評分差值大于對照組,而實驗1組患者頭顱血腫體積差值及NIHSS評分差值大于實驗2組,并具有統(tǒng)計學(xué)意義(P0.05)。結(jié)論:1.高血壓性腦出血后在沒有禁忌的情況下可于發(fā)病1周后應(yīng)用EGB761進(jìn)行治療,可顯著縮短腦出血后血腫的吸收時間,改善神經(jīng)功能缺損和預(yù)后。2.在高血壓性腦出血較早期應(yīng)用EGB761并沒有增加顱內(nèi)再出血及其他不良反應(yīng)的概率。
[Abstract]:Objective: to study the application of EGb761 in hypertensive intracerebral hemorrhage and to evaluate the safety of EGB 761 in patients with hypertensive intracerebral hemorrhage. To provide theoretical support for the application of Ginkgo biloba extract in cerebral hemorrhage. Methods: from June 2015 to September 2016, 90 patients with hypertensive intracerebral hemorrhage in unilateral basal ganglia who were hospitalized in Department of Neurology, Shanxi Provincial people's Hospital, were divided into two groups according to their admission order. There were 30 cases in test group 2 and 30 cases in control group. Complete general records of all patients at the time of admission, including age of registration, systolic blood pressure, diastolic blood pressure, body temperature, blood glucose at admission, admission delay time, At the same time, the data of NIHSS score of cranial CT hematoma volume and so on were collected on the same day. 3 groups were all in accordance with the guidelines of Chinese Cerebrovascular Disease Prevention and treatment issued by the Chinese Medical Association in 2014 to determine the treatment plan. Group 1 was treated with EGb761 injection 70mg once a day at 1 week after onset, group 2 was treated with EGb761 injection 70mg once a day for 14 days after onset, and the data of head CT hematoma volume and NIHSS score were collected at the same time. The difference between CT hematoma volume and NIHSS score was obtained, and the difference of neurological deficit score and hematoma volume was recorded in three groups. After the completion of the data collection, spss17.0 statistical software for data processing, ANOVA is used to predict whether there is a difference between groups, SNK-q test is used to carry out a comprehensive comparison between the two groups of the average, P05 presupposition has statistical significance. Results the age at admission, systolic and diastolic blood pressure, immediate blood glucose, body temperature, The difference of the volume of intracranial hematoma and the difference of NIHSS score between the two groups were consistent with normal distribution and homogeneity of variance. The variance analysis showed that the difference of hematoma volume and NIHSS score was different among the three groups, and the difference was statistically significant (P0.05. 3). By comparing the volume difference of intracranial hematoma and the difference of NIHSS score between the three groups, it was found that there were differences in the volume difference of cranial hematoma and NIHSS score between the control group and experimental group 1, control group and experimental group 2, experimental group 2 and experimental group 1. The difference in volume of cranial hematoma and NIHSS score in experimental group 2 was higher than that in control group, while the difference in volume of cranial hematoma and NIHSS score in group 1 was higher than that in group 2, and had statistical significance (P 0.05). Conclusion 1. EGB761 can be used in the treatment of hypertensive intracerebral hemorrhage 1 week after the onset without contraindication, which can significantly shorten the time of hematoma absorption, improve the neurological function defect and prognosis. 2. Early application of EGB761 in hypertensive intracerebral hemorrhage did not increase the probability of intracranial rebleeding and other adverse reactions.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R743.34

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉文鵬;劉艷;魏燦;于建剛;陳愛民;丁云龍;管清華;王瑩;;T細(xì)胞蛋白酪氨酸磷酸酶和內(nèi)皮脂酶基因多態(tài)性與出血性腦卒中的相關(guān)性研究[J];中華老年心腦血管病雜志;2016年09期

2 匡yN;陳偉建;鄭葵葵;付軍;胡子龍;楊運俊;戴一川;;CT灌注成像評估急性自發(fā)性腦出血周圍組織血流動力學(xué)變化[J];中華醫(yī)學(xué)雜志;2015年43期

3 陳澤鵬;;超早期微創(chuàng)穿刺引流術(shù)治療基底節(jié)區(qū)腦出血的療效觀察[J];中國社區(qū)醫(yī)師;2014年29期

4 梁柱樓;陳學(xué)華;胡振華;胡偉康;;不同手術(shù)方法治療高血壓腦出血的對照研究[J];中國當(dāng)代醫(yī)藥;2012年30期

5 江漢秋;劉群;陳志;張昱;;凝血酶致大鼠腦水腫與腦內(nèi)MMP-9、MMP-2蛋白表達(dá)關(guān)系的實驗研究[J];中國實驗診斷學(xué);2010年09期

6 趙國有;;腦出血患者血清腫瘤壞死因子α、白細(xì)胞介素6和C-反應(yīng)蛋白的檢測及意義[J];中國煤炭工業(yè)醫(yī)學(xué)雜志;2008年05期

7 張春銀;李作孝;譚華;李曉紅;劉科;;尼莫地平對腦出血后缺血性腦損害保護作用的研究[J];中華老年心腦血管病雜志;2006年05期

8 吳萬福,胡長林;炎性細(xì)胞因子在腦出血繼發(fā)性腦損害中的作用[J];國外醫(yī)學(xué)(腦血管疾病分冊);2005年04期

9 楊期東,周艷宏,劉運海,許宏偉,田發(fā)發(fā),谷文萍,張樂,夏健;長沙社區(qū)人群腦卒中患者發(fā)病的監(jiān)測研究[J];中華醫(yī)學(xué)雜志;2003年04期

10 呂云利,付學(xué)鋒,路奎,廖軍,徐文武;實驗性大鼠腦出血急性期血漿和腦組織中胰島素樣生長因子-1的含量[J];第四軍醫(yī)大學(xué)學(xué)報;2001年15期

，

本文編號：1926740